A phase I, randomized, single-blind, single-dose, single-centre, placebo-controlled crossover study evaluating pulmonary deposition of radiolabelled glycopyrronium/formoterol delivered by Co-Suspension™ Technology MDI in healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2018
At a glance
- Drugs Formoterol/glycopyrrolate (Primary) ; Tc 99m pertechnetate
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- 05 Jan 2017 New trial record